| ［1］ |
中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识（2014版）［J］. 中华皮肤科杂志, 2014, 47（3）: 213⁃215. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.017.
|
|
Psoriasis Group of Chinese Society of Dermatology. Consensus on the treatment of psoriasis in China （2014） ［J］. Chin J Dermatol, 2014, 47（3）: 213⁃215. DOI: 10.3760/cma.j.issn.0412⁃4030.2014.03.017.
|
| ［2］ |
Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen⁃induced arthritis in mice［J］. J Immunol, 1993, 151（11）: 6602⁃6607.
|
| ［3］ |
黄琼, 杨勤萍, 方栩, 等. 重组人Ⅱ型肿瘤坏死因子受体⁃抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验［J］. 中华皮肤科杂志, 2007, 40（11）： 655⁃658. DOI: 10.3760/j.issn:0412⁃4030.2007.11.001.
|
|
Huang Q, Yang QP, Fang X, et al. Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor: Fc fusion protein: a multicentre, randomized, double blind trial［J］. Chin J Dermatol, 2007, 40（11）： 655⁃658. DOI: 10.3760/j.issn:0412⁃4030.2007.11.001.
|
| ［4］ |
Gisondi P, Del GM, Cotena C, et al. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24⁃week, randomized, controlled, investigator⁃blinded pilot trial［J］. Br J Dermatol, 2008, 158（6）: 1345⁃1349. DOI: 10.1111/j.1365⁃2133.2008.08564.x.
|
| ［5］ |
Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as mono⁃therapy in patients with psoriasis［J］. N Engl J Med, 2003, 349（21）: 2014⁃2022. DOI: 10.1056/NEJMoa030409.
|
| ［6］ |
Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction［J］. Br J Dermatol, 2005, 152（6）: 1304⁃1312. DOI: 10.1111/j.1365⁃2133.2005.06688.x.
|
